iCAD to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Wednesday, February 20, 2013

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of
advanced image analysis, workflow solutions and radiation therapy for
the early identification and treatment of cancer, today announced that
the Company will release financial results for the three and twelve
months ended December 31, 2012, following the close of the market on
Tuesday, February 19, 2013.

Ken Ferry, President and Chief Executive Officer, and Kevin C. Burns,
Executive Vice President and Chief Financial Officer, will host a
conference call for investors beginning at 10:00 a.m. ET on Wednesday,
February 20, 2013 to discuss the fourth quarter and full year 2012
financial results and to answer questions.

Shareholders and other interested parties may participate in the
conference call by dialing 800- 591-6930 (domestic) or 617-614-4908
(international) and entering passcode 60116734. The call also will be
broadcast live on the Internet at www.streetevents.com,
www.fulldisclosure.com
and www.icadmed.com.

A replay of the conference call will be accessible two hours after its
completion through February 27, 2013 by dialing 888-286-8010 (domestic)
or 617-801-6888 (international) and entering passcode 71898017. The call
will also be archived for 90 days at www.streetevents.com,
www.fulldisclosure.com
and www.icadmed.com.

About iCAD, Inc.

iCAD is an industry-leading provider of advanced image analysis,
workflow solutions and radiation therapies for the early identification
and treatment of common cancers. iCAD offers a comprehensive range of
high-performance, upgradeable CAD solutions for mammography and advanced
image analysis and workflow solutions for Magnetic Resonance Imaging,
for breast and prostate cancers and Computed Tomography for colorectal
cancer. iCAD’s Xoft System offers radiation treatment for early-stage
breast cancer that can be administered in the form of intraoperative
radiation therapy or accelerated partial breast irradiation. The Xoft
System is also cleared for the treatment of non-melanoma skin cancer and
endometrial cancer. For more information, call 877-iCADnow, or visit www.icadmed.com.

Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited
to, the Company’s ability to defend itself in litigation matters, the
risks relating to the Company’s acquisition of Xoft including, the
expected benefits of the acquisition may not be achieved in a timely
manner, or at all; the Xoft business operations may not be successfully
integrated with iCAD’s and iCAD may be unable to achieve the expected
synergies, business and strategic objectives following the transaction,
the risks of uncertainty of patent protection; the impact of supply and
manufacturing constraints or difficulties; product market acceptance;
possible technological obsolescence; increased competition; customer
concentration; and other risks detailed in the Company’s filings with
the Securities and Exchange Commission. The words “believe”,
“demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”,
“anticipate”, “likely”, and similar expressions identify forward-looking
statements. Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any
updates to any information contained in this release. For additional
disclosure regarding these and other risks faced by iCAD, please see the
disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website
at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.